Menlo Park investment firm Sofinnova Ventures has raised $440 million for its Sofinnova Venture Partners VIII. It is looking to invest in later-stage healthcare companies in the U.S. and in foreign countries, and is primarily eying European markets.
The firm will primarily target clinical-stage drug development and offshoots. The fund’s partners include Jim Healy, Garheng Kong, Mike Powell, Anand Mehra, Lars Ekman and David Kabakoff.
Click here for the release from Sofinnova.